"I provide an extremely thorough work-up and evaluation."

During the past decade, Ritchken and First MD's conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 9 clinical trials were completed, i.e. on average, 900% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ritchken and First MD's" #1 sponsor was "AstraZeneca" with 5 trials, followed by "Pfizer" with 2 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored, "Brigham and Women's Hospital" with 1 trials sponsored and "Eisai Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ritchken and First MD's" #1 collaborator was "Bristol-Myers Squibb" with 2 trials as a collaborator, "Astra Zeneca, Bristol-Myers Squibb" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Ritchken and First MD's" are "Type 2 Diabetes" (5 trials), "Cardiovascular Disease" (4 trials), "Type 2 Diabetes Mellitus" (2 trials), "Acute Gout" (1 trials) and "Atrial Fibrillation" (1 trials). Many other conditions were trialed in "Ritchken and First MD's" in a lesser frequency.

Most popular intervention types in "Ritchken and First MD's" are "Drug" (12 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Dapagliflozin" (3 trials), "Metformin" (3 trials), "bococizumab (PF-04950615)" (2 trials) and "Canakinumab 150 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ritchken and First MD's" are 13 trials for "All" genders.

Currently, there are NaN active trials in "Ritchken and First MD's". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Ritchken and First MD's, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Ritchken and First MD's, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Ritchken and First MD's has several departments that took part in Clinical trials: "Sharp Clinical Oncology Research" - 36 trials, "Sharp Memorial Hospital Cancer Center" - 4 trials